Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Zymeworks Inc

ZYME ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Small Cap Analyst: BUY

Last Close

$27.47

▼ -4.52%

Market Cap $1.95B · Vol 584.31K

Key Metrics

P/E Ratio

N/A

FWD: 20.37

Market Cap

$1.95B

Small Cap

Div Yield

N/A

EPS Growth

+224.44%

YoY

RSI (14)

70.11

Momentum

Beta

1.17

vs Market

52W High

$30.39

9.59% below

52W Low

$13.66

101.10% above

Volume

584.31K

Avg 199.69K

P/B

7.37

Price-to-book

ROE

-26.72%

Return on equity

Free Float

92.79%

Public shares

Shariah Compliance8 STANDARDS

✗ Zymeworks Inc (ZYME) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does ZYME pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+5.37%

+20.17%

+7.26%

+13.89%

YTD

+4.33%

+88.54%

+256.75%

-15.71%

Financials & Valuation

TTM · Annual

Total Revenue	$105.97M
Net Income	$-81,130,000.00
Revenue Growth (YoY)	-90.58%
Gross Margin	100.00%
Operating Margin	-87.34%
Net Profit Margin	-76.56%
ROE	-26.72%
ROA · ROIC	-19.70% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	20.37
PEG Ratio	N/A
P/S	18.74
P/B	7.37
P/FCF	N/A
EPS Growth	+224.44%
Outstanding Shares	70.96M

Technical Indicators

50-Day SMA	$24.53
200-Day SMA	$24.56
RSI (14)	70.11
Beta	1.17
52-Week High	$30.39
52-Week Low	$13.66

Volume Today	584.31K
Avg Daily Volume (30D)	199.69K
Relative Volume	2.93x
Volatility (10D)	55.01
Volatility (30D)	43.33
Free Float	92.79%

Analyst Consensus

BUY

Current Price $27.47

Mean Target $40.92

52W Low$13.66 52W High$30.39

Current

Target

$13.66 $30.39

Current Analyst target

+48.95% upside potential · 13 analysts

Identifiers

ExchangeNasdaq

FIGIBBG019XSYC98

ISINUS98985Y1082

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 4, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd +3.29% ARGX.BR argenx SE +1.74% ARGX argenx SE +0.83% 2269.HK WuXi Biologics (Cayman) Inc +7.41% INSM Insmed Inc -0.07%

Company Profile

Zymeworks Inc. is a biotechnology company. The Company is engaged in managing a portfolio of healthcare assets and developing a pipeline of multifunctional biotherapeutics to improve the standard of care for conditions, including cancer, inflammation, and autoimmune disease. Its antibody-drug conjugates (ADCs) include ZW191, ZW251, and ZW220. ZW191 is a clinical-stage ADC that targets folate receptor alpha-expressing tumors including ovarian cancer, endometrial cancer, and non-small cell lung cancer (NSCLC), which is built using bystander-active, TOPO1i payload technology, ZD06519. ZW251 is a clinical-stage ADC molecule designed for the treatment of glypican 3 (GPC3)-expressing hepatocellular carcinoma (HCC). ZW220 is an ADC that targets NaPi2b-expressing NSCLC and ovarian cancer, built using bystander active TOPO1i payload technology, ZD06519. Its therapeutic platforms can be used to develop multifunctional fit-for-purpose biotherapeutics with bispecific capabilities.